Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer

Romanian Journal of Morphology and Embryology

Volumn 51, Issue 1, 2010, Pages 85-89

  Zaha, Dana Carmen ^a   Lazǎr, Elena ^b   Lǎzureanu, Codruţa ^b  

^a UNIVERSITY OF ORADEA   (Romania)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Breast cancer; Clinicopathologic features; Molecular classification

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; CARCINOMA; CLASSIFICATION; DIAGNOSTIC PROCEDURE; EVALUATION; FEMALE; HUMAN; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; TIME; EVALUATION STUDY; MOLECULAR DIAGNOSIS; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949375203     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 2001, 98(19):10869-10874.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 1987, 235(4785):177-182.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA, 2006, 295(21):2492-2502.
4. Iwase H, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Toyama T, Hara Y, Kobayashi S, Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer, Cancer Detect Prev, 1997, 21(1):29-35.
5. Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y, Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers, BMC Cancer, 2008, 8:309.
6. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI, The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro, Endocrinology, 2003, 144(11):5105-5117.
7. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE, A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses, Breast Cancer Res Treat, 2008, 112(3):533-543.
8. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET, Breast cancer classification and prognosis based on gene expre- ssion profiles from a population-based study, Proc Natl Acad Sci U S A, 2003, 100(18):10393-10398.
9. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L, Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res, 2005, 11(16):5678-5685.